ID30485A - Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4 - Google Patents

Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4

Info

Publication number
ID30485A
ID30485A IDW00200101892A ID20011892A ID30485A ID 30485 A ID30485 A ID 30485A ID W00200101892 A IDW00200101892 A ID W00200101892A ID 20011892 A ID20011892 A ID 20011892A ID 30485 A ID30485 A ID 30485A
Authority
ID
Indonesia
Prior art keywords
pyrimidine
amino
metylsulfonyl
methodsulfonyl
isoenzim
Prior art date
Application number
IDW00200101892A
Other languages
English (en)
Indonesian (id)
Inventor
Ali Raza
John Stuart Pears
Howard Gerard Hutchinson
Dennis Schneck
Takahiko Baba
Akira Touchi
Yoshitaka Yamaguchi
Original Assignee
Astrazeneca Ab
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID30485(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Application filed by Astrazeneca Ab, Shionogi & Co filed Critical Astrazeneca Ab
Publication of ID30485A publication Critical patent/ID30485A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IDW00200101892A 1999-02-06 2000-02-01 Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4 ID30485A (id)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination

Publications (1)

Publication Number Publication Date
ID30485A true ID30485A (id) 2001-12-13

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101892A ID30485A (id) 1999-02-06 2000-02-01 Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4

Country Status (28)

Country Link
US (3) US6982157B1 (cg-RX-API-DMAC7.html)
EP (1) EP1185274B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002536331A (cg-RX-API-DMAC7.html)
KR (2) KR20010101790A (cg-RX-API-DMAC7.html)
CN (1) CN1165310C (cg-RX-API-DMAC7.html)
AR (1) AR029333A1 (cg-RX-API-DMAC7.html)
AT (1) ATE282415T1 (cg-RX-API-DMAC7.html)
AU (1) AU767304B2 (cg-RX-API-DMAC7.html)
BR (1) BR0007999A (cg-RX-API-DMAC7.html)
CA (1) CA2358632C (cg-RX-API-DMAC7.html)
CZ (1) CZ301296B6 (cg-RX-API-DMAC7.html)
DE (1) DE60015965T2 (cg-RX-API-DMAC7.html)
EE (1) EE04929B1 (cg-RX-API-DMAC7.html)
EG (1) EG23858A (cg-RX-API-DMAC7.html)
ES (1) ES2232418T3 (cg-RX-API-DMAC7.html)
GB (1) GB0000710D0 (cg-RX-API-DMAC7.html)
ID (1) ID30485A (cg-RX-API-DMAC7.html)
IL (1) IL144715A0 (cg-RX-API-DMAC7.html)
IS (1) IS2337B (cg-RX-API-DMAC7.html)
MX (1) MXPA01007905A (cg-RX-API-DMAC7.html)
MY (1) MY130606A (cg-RX-API-DMAC7.html)
NO (1) NO320745B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ512982A (cg-RX-API-DMAC7.html)
PL (1) PL198034B1 (cg-RX-API-DMAC7.html)
PT (1) PT1185274E (cg-RX-API-DMAC7.html)
TR (1) TR200102228T2 (cg-RX-API-DMAC7.html)
TW (1) TWI282738B (cg-RX-API-DMAC7.html)
WO (1) WO2000045817A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156422A0 (en) 2001-01-26 2004-01-04 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
JP5069001B2 (ja) 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MX2007001553A (es) 2004-08-06 2008-03-07 Transform Pharmaceuticals Inc Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados.
EP1948600B1 (en) * 2005-07-05 2014-04-16 The President & Fellows Of Harvard College Liver targeted conjugates
EA015682B1 (ru) 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
WO2019241519A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
MX2022001178A (es) * 2019-07-31 2022-02-22 Intas Pharmaceuticals Ltd Composicion farmaceutica que comprende inhibidores de la hmg-coa reductasa y fenofibrato.
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DK0521417T3 (da) * 1991-07-02 1995-03-27 Benckiser Gmbh Joh A Sammenklappelig forrådsflaske
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
AU1289899A (en) * 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity

Also Published As

Publication number Publication date
BR0007999A (pt) 2001-11-06
PL198034B1 (pl) 2008-05-30
TR200102228T2 (tr) 2002-03-21
KR20060117381A (ko) 2006-11-16
JP2007277267A (ja) 2007-10-25
MY130606A (en) 2007-07-31
NO20013811D0 (no) 2001-08-03
IS2337B (is) 2008-02-15
EE04929B1 (et) 2007-12-17
AR029333A1 (es) 2003-06-25
IS6009A (is) 2001-07-17
PT1185274E (pt) 2005-03-31
AU767304B2 (en) 2003-11-06
DE60015965D1 (de) 2004-12-23
PL364780A1 (en) 2004-12-13
WO2000045817A1 (en) 2000-08-10
AU2121800A (en) 2000-08-25
US20090042911A1 (en) 2009-02-12
NO320745B1 (no) 2006-01-23
CN1338936A (zh) 2002-03-06
CN1165310C (zh) 2004-09-08
CA2358632A1 (en) 2000-08-10
CA2358632C (en) 2008-10-28
HK1041817A1 (en) 2002-07-26
US20060040969A1 (en) 2006-02-23
MXPA01007905A (es) 2003-06-04
NO20013811L (no) 2001-10-02
IL144715A0 (en) 2002-06-30
EG23858A (en) 2007-11-18
JP2002536331A (ja) 2002-10-29
TWI282738B (en) 2007-06-21
GB0000710D0 (en) 2000-03-08
ATE282415T1 (de) 2004-12-15
DE60015965T2 (de) 2006-01-05
KR20010101790A (ko) 2001-11-14
NZ512982A (en) 2003-08-29
CZ20012844A3 (cs) 2001-11-14
US6982157B1 (en) 2006-01-03
ES2232418T3 (es) 2005-06-01
CZ301296B6 (cs) 2010-01-06
EE200100406A (et) 2002-10-15
EP1185274A1 (en) 2002-03-13
EP1185274B1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
ID30485A (id) Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
AU3569800A (en) Pyrimidine compounds with pharmaceutical activity
DE59812907D1 (de) Substituierte Isochinolin-3-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
BRPI0013439B8 (pt) composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
EP1263453A4 (en) PHARMACEUTICAL FORMULATION FOR REGULATING THE RELEASE IN TIME OF BIOLOGICALLY ACTIVE COMPOUNDS BASED ON A POLYMERIC MATRIX
AU1979501A (en) Optically active materials
AU3813499A (en) The use of dihydropyrimidines as medicaments, and novel substances
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
AU3157801A (en) Beta-amino acid compounds as integrin antagonists
BR9807814B1 (pt) composto de pirazina, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
PT1169460E (pt) Preparacao de moleculas biologicamente activas.
AU2003252299A1 (en) Novel physiologically active substance
AU5210798A (en) Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
BR0014465B1 (pt) 1,1'-bifenil-2-carbonamidas 2'-substituÍdas, preparado farmacÊutico e aplicaÇÕes dos referidos compostos.
DZ3155A1 (fr) Nouvelle composition pharmaceutique.
AU2759800A (en) Processes and intermediates for the preparation of 1,3-oxazin-6-ones and uracils
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU5073400A (en) Sulfonamide compounds with pharmaceutical activity
DE50305374D1 (de) Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
ZA200201521B (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparation containing the same, and methods of using the same.
AU5404800A (en) Process for the preparation of optically active n-acyl derivatives of methyl n-(2,6-dimethylphenyl)-d-alaninate
HUP0203275A3 (en) 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants
CA2379314A1 (en) Tablet for sucking, containing ambroxol